Fischer Medical Ventures highlighted its strategic partnership with Nanyang Biologics, reinforcing its commitment to bringing advanced Artificial Intelligence (AI)-powered molecular research technologies to India and supporting the country's pharmaceutical and life sciences ecosystem.

Through this partnership, Fischer Medical Ventures aims to introduce AI-enabled molecular research capabilities to India, foster association with pharmaceutical companies, biotechnology innovators, academic institutions and research organisations, and accelerate the discovery of novel therapeutic molecules. By combining AI with India's scientific expertise and rich botanical and Ayurvedic heritage, the partnership seeks to support evidence-based therapeutic innovation, subject to scientific validation and regulatory approvals.

A key part of the collaboration is Vecura, Nanyang Biologics' advanced molecular research platform that enables researchers to simulate molecular behavior, predict material properties and conduct high-throughput computational analysis to accelerate research and therapeutic discovery.